GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IntelliPharmaCeutics International Inc (OTCPK:IPCIF) » Definitions » 6-1 Month Momentum %

IntelliPharmaCeutics International (IntelliPharmaCeutics International) 6-1 Month Momentum % : 33.33% (As of Apr. 27, 2024)


View and export this data going back to 1996. Start your Free Trial

What is IntelliPharmaCeutics International 6-1 Month Momentum %?

6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2024-04-27), IntelliPharmaCeutics International's 6-1 Month Momentum % is 33.33%.

The industry rank for IntelliPharmaCeutics International's 6-1 Month Momentum % or its related term are showing as below:

IPCIF's 6-1 Month Momentum % is ranked worse than
59.2% of 1522 companies
in the Biotechnology industry
Industry Median: 4.02 vs IPCIF: 33.33

Competitive Comparison of IntelliPharmaCeutics International's 6-1 Month Momentum %

For the Biotechnology subindustry, IntelliPharmaCeutics International's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IntelliPharmaCeutics International's 6-1 Month Momentum % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IntelliPharmaCeutics International's 6-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where IntelliPharmaCeutics International's 6-1 Month Momentum % falls into.



IntelliPharmaCeutics International  (OTCPK:IPCIF) 6-1 Month Momentum % Calculation

6-1 Month Momentum % is calculated as following:

6-1 Month Momentum %=( Price 1-month ago / Price 6-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


IntelliPharmaCeutics International  (OTCPK:IPCIF) 6-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.


IntelliPharmaCeutics International 6-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of IntelliPharmaCeutics International's 6-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.


IntelliPharmaCeutics International (IntelliPharmaCeutics International) Business Description

Traded in Other Exchanges
Address
30 Worcester Road, Toronto, ON, CAN, M9W 5X2
IntelliPharmaCeutics International Inc is a pharmaceutical company. The company is engaged in the research, development, and manufacturing of novel and generic controlled-release and targeted-release oral solid dosage drugs. Its patented Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to the development of a range of existing and new pharmaceuticals. Its ongoing drug development programs are at various stages of development in therapeutic areas that include neurology, cardiovascular, GIT, and pain. The company's product, a generic of Focalin XR, is partnered with Par Pharmaceutical, Inc. and received FDA approval. It derives revenue from the United States.